Nuvation Bio enrolls first patient in phase 3 lung cancer trial
PositiveFinancial Markets

Nuvation Bio has successfully enrolled its first patient in a phase 3 clinical trial aimed at treating lung cancer. This milestone is significant as it marks a crucial step in the development of new therapies for a disease that affects millions worldwide. The trial's outcomes could potentially lead to innovative treatment options, improving survival rates and quality of life for patients battling this challenging illness.
— Curated by the World Pulse Now AI Editorial System